What in the World Is Going on With Novavax Stock?
It's a cliche to say that certain stocks are like roller coaster rides, but the coronavirus vaccine developer Novavax (NASDAQ: NVAX) has given a completely new meaning to the term over the last 12 months. While it's up more than 64% this year, in the last three months shareholders have taken losses of about 27%, which means that many of the people who bought shares at the peak early this year are likely to be displeased.
Still, in the last month alone, Novavax's stock has climbed sharply as the company scored crucial approvals for its vaccine and started commercialization of its vaccine in international markets like the Philippines and Indonesia. And the omicron variant appears to have juiced it even further.
But as a result of even more delays with its manufacturing and the filing of a class action lawsuit by shareholders, things are far from settled. Especially for investors who are wondering whether to keep holding Novavax, it's worth investigating what's going on in more detail.
Source Fool.com